1 citations
,
September 2020 in “Cochrane library (CD-ROM)” The analysis aims to identify the most effective and safest treatments for alopecia areata.
January 2026 in “Immune Network” Regulatory T cells adapt to different environments to control inflammation and support tissue repair.
July 2011 in “British Journal of Dermatology” Dermatologists give better information on pathology forms, hypersensitivity vasculitis is a common skin issue, misdiagnoses can occur, and various skin conditions are linked to loss of elastin or genetic factors.
70 citations
,
October 2020 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Janus kinase inhibitors are promising drugs for treating autoimmune and inflammatory diseases.
2 citations
,
May 2024 in “Australasian Journal of Dermatology” Early diagnosis, innovative treatments, and considering systemic conditions are crucial in dermatological care.
4 citations
,
May 2023 in “Cells” Baricitinib and its combination with lonafarnib improve fat cell formation in certain genetic disorders.
January 2025 in “International Journal of Pharmaceutics” The treatment showed significant hair regrowth in alopecia areata patients without side effects.
4 citations
,
March 2025 in “The Journal of Dermatology” Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.
January 2025 in “Dermatologic Therapy” Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.
3 citations
,
May 2025 in “Carbohydrate Polymers” The new microneedle patch effectively treats alopecia areata with fewer side effects than oral medication.
15 citations
,
December 2018 in “International journal of environmental research and public health/International journal of environmental research and public health” EGCG may help treat alopecia areata by blocking certain immune responses and reducing specific harmful immune cells.
December 2025 in “Cosmetics” New treatments for alopecia show promise in restoring hair growth by targeting immune and hormonal factors.
489 citations
,
November 2021 in “Signal Transduction and Targeted Therapy” The JAK/STAT pathway is important in cell processes and disease, and JAK inhibitors are promising for treating related conditions.
45 citations
,
May 2024 in “International Journal of Molecular Sciences” Alopecia areata is caused by immune attacks on hair follicles, affecting hair growth and quality of life.
1 citations
,
May 2025 in “Journal of Cosmetic Dermatology” Blood metabolites significantly influence alopecia areata risk.
February 2026 in “Journal of Allergy and Clinical Immunology” Alopecia areata involves immune system issues and specific cell types that disrupt hair growth, leading to hair loss.
46 citations
,
April 2020 in “Drugs” Emerging therapies like JAK inhibitors show promise for hair regrowth in alopecia areata.
8 citations
,
May 2025 in “Pharmaceuticals” In 2024, the FDA approved 27 innovative small-molecule drugs, with many offering significant treatment improvements.
2 citations
,
November 2019 in “International Journal of Dermatology and Venereology” Chronic autoimmune urticaria can be managed with specific therapies and requires improved diagnosis and treatment methods.
January 2026 in “Journal of Investigative Dermatology” Special cells can help regrow hair in alopecia areata.
May 2025 in “JEADV Clinical Practice” Hair specialists vary in testing for alopecia areata, highlighting the need for standard guidelines.
August 2024 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.
48 citations
,
April 2021 in “Journal of the American Academy of Dermatology” Topical corticosteroids are the best initial treatment for children's alopecia areata.
August 2022 in “IntechOpen eBooks” The best treatment for Frontal Fibrosing Alopecia and Lichen Planopilaris combines oral and topical medications to reduce symptoms and stop hair loss.
December 2025 in “Journal of health economics and outcomes research” Alopecia areata in Saudi Arabia is costly, mainly due to lost productivity and drug costs.
22 citations
,
April 1998 in “Dermatologic Clinics” Interferons are effective for some skin conditions and cancers, but can have side effects and need more research for optimal use.
68 citations
,
November 2015 in “The Journal of Allergy and Clinical Immunology” Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.
66 citations
,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
August 2019 in “Journal of The American Academy of Dermatology” RV3466F lotion significantly reduces hair loss and improves acute telogen effluvium.
11 citations
,
February 2021 in “Journal of Cosmetic Dermatology” Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.